Canada: Life Sciences, Biotechnology & Nanotechnology

On July 23, 2025, Environment and Climate Change Canada (ECCC) announced the release of the Plan of Priorities, a multi-year plan that outlines upcoming priorities for the assessment of chemical substances.

On August 8, 2025, the Federal Court of Appeal (FCA) determined that the Minister of Health's decision to list Canadian Patent No. 2,970,315 on the Patent Register eight days...

Important amendments to the Exception Patient Measure came into effect on June 2, 2025. A summary of the key changes is provided below.

TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal (FCA) to overturn the refusal of the Minister of Mental Health...

This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access—since our March 2024 update.

In the Patented Medicine Prices Review Board (PMPRB)'s June 2025 NEWSletter, Acting Chairperson Anie Perrault confirms that the PMPRB plans on publishing its final Guidelines in summer 2025.

On April 16, 2025, the Government of Canada issued the "United States Surtax Remission Order (2025)" (the "Remission Order") pursuant to section 115 of the Customs Tariff, which was followed by the release of a customs notice on the application of the Remission Order (the "Customs Notice") by the Canada Border Services Agency.

The ongoing expansion of Neurotechnology (or "neurotech") for consumers is raising questions related to privacy and ownership of one's thoughts, as well as what will happen when technology can go beyond...

The use of artificial intelligence ("AI") in healthcare creates transformational opportunities to improve systems and care, while also testing existing regulatory pathways...